Drug intelligence / Profile preview

luminespib + pemetrexed

Development stage: Unknown
Lead developer: Ligand Pharmaceuticals
Modality: Small Molecules
Administration: Intravenous

Overview

Luminespib (AUY922) is a second-generation heat shock protein 90 (HSP90) inhibitor with demonstrated activity in non-small cell lung cancer (NSCLC). Pemetrexed is an antifolate chemotherapy agent. The combination of luminespib and pemetrexed has been investigated for the treatment of previously treated metastatic non-squamous NSCLC. Luminespib reduces levels of dihydrofolate reductase (DHFR), a key enzymatic target of pemetrexed, which may enhance the therapeutic effect. Clinical studies have shown that this combination demonstrates clinical activity, but tolerability is limited by ocular toxicity[1].

Targets

DHFR (Dihydrofolate reductase)GART (GAR transformylase)HSP90 (Heat shock protein 90 chaperone complex)TS (Thymidylate synthase)

Beyond the preview

Go deeper on luminespib + pemetrexed.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on luminespib + pemetrexed.

Explore the full profile